journal of men's health
Volume 7, Issue 2 , Pages 113-124 , June 2010

Managing benign prostatic hyperplasia and prostate cancer – the challenges today

Received 19 August 2009 ,Revised 16 December 2009 ,Accepted 17 December 2009.

References 

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592
  2. Issa MM, Regan TS. Medical therapy for benign prostatic hyperplasia–present and future impact. Am J Manag Care. 2007;13(Suppl 1):S4–9
  3. Meigs JS, Barry MJ. Natural history of benign prostatic hyperplasia. In:  Kirby R,  McConnell JD,  Fitzpatrick JM editor. Textbook of Benign Prostatic Hyperplasia.. Oxford, UK: Isis Medical Media Ltd; 1996;p. 125–138
  4. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int. 2005;95(1):15–19
  5. Bacon CG, Kawachi I. Quality-of-life differences among various populations of localized prostate cancer patients: 2001. Curr Urol Rep. 2002;3(3):239–243
  6. Mellon S, Northouse LL. Family survivorship and quality of life following a cancer diagnosis. Res Nurs Health. 2001;24(6):446–459
  7. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395
  8. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524–3530
  9. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80
  10. Ries LAG, Melbert D, Krapcho M. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007;
  11. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91(9):789–794
  12. Schroder FH, Roobol MJ, Andriole GL, Fleshner N. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181(1):69–74discussion
  13. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25(4):431–436
  14. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58(3):411–416
  15. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
  16. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46(5):547–554
  17. Cancer Research UK. CancerStats Key Facts: Prostate Cancer. Available at: http://info.cancerresearchuk.org/cancerstats/types/prostate/.[Accessed 20th August 2008].
  18. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N Engl J Med. 2004;350(22):2239–2246
  19. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695–2700
  20. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Pt 2):841–845
  21. Resnick M, Ackerman R, Bosch J, Cidre J, Foo K, Frand I. Fifth International Consultation on BPH. In:  Chatelain C,  Denis L,  Foo S,  Khoury S,  McConnell JD editor. Benign Prostatic Hyperplasia. Plymbridge Distributions. 2000;p. 169–188
  22. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med. 1997;126(5):394–406
  23. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2):95–101
  24. National Comprehensive Cancer Network. Prostate Cancer Early Detection, version 2; 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf.
  25. American Cancer Society. Guidelines for the Early Detection of Cancer. Revised 3rd May 2008. Available at: http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp?sitearea=PED.
  26. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer. 1997;80(9):1857–1863
  27. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–878
  28. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328
  29. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319
  30. National Health Service (NHS). Prostate Cancer Risk Management: UK Information Pack 2002. Available from: http://www.cancerscreening.nhs.uk/prostate/prostate-booklet-text.pdf [Accessed 20th August 2008].
  31. Busby JE, Evans CP. Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis. 2004;7(2):93–98
  32. Park SJ, Miyake H, Hara I, Eto H. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol. 2003;10(2):68–71
  33. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997;1:1–96
  34. Puig J, Darnell A, Bermudez P, Malet A, Serrate G, Bare M, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?. Eur Radiol. 2006;16(4):939–943
  35. Sheikh M, Hussein AY, Kehinde EO, Al-Saeed O, Rad AB, Ali YM, et al. Patients’ tolerance and early complications of transrectal sonographically guided prostate biopsy: prospective study of 300 patients. J Clin Ultrasound. 2005;33(9):452–456
  36. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001;166(5):1679–1683
  37. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–2131
  38. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–1261
  39. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol. 2006;8(Suppl 2):S35–47
  40. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol. 2005;47(1):16–21
  41. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev Urol. 2004;6(Suppl 9):S53–S59
  42. Norby B, Nordling J, Mortensen S. Lower urinary tract symptoms in the Danish population: a population-based study of symptom prevalence, health-care seeking behavior and prevalence of treatment in elderly males and females. Eur Urol. 2005;47(6):817–823
  43. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008;62(1):18–26
  44. de la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol. 2001;40(3):256–263discussion 64
  45. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). 2003. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/chapt_1_appendix.pdf.
  46. Fawzy A, Fontenot C, Guthrie R, Baudier MM. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med. 1997;29(5):321–325
  47. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61(2):267–273
  48. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398
  49. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol. 2004;45(4):411–419
  50. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–487
  51. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. 1999;54(4):662–669
  52. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39(4):390–399
  53. Roehrborn CG, Girman CJ, Rhodes T, Hanson KA, Collins GN, Sech SM, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 1997;49(4):548–557
  54. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology. 1998;51(4A Suppl):19–22
  55. Bartsch G, Fitzpatrick JM, Schalken JA, Isaacs J, Nordling J, Roehrborn CG. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int. 2004;93(Suppl 1):27–29
  56. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–494discussion 95
  57. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557–563
  58. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176(3):868–874
  59. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006;175(5):1657–1662
  60. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol. 1996;155(1):3–9
  61. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128–1133
  62. Roehrborn CG. Alfuzosin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int. 2006;97(4):734–741
  63. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422–1426discussion 6-7
  64. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25ml or greater. J Urol. 2006;175(1):217–220discussion 20-1
  65. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007;28(6):770–779
  66. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131
  67. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol. 1999;6(3):819–822
  68. Teillac P. [Benign prostatic hyperplasia: patients’ perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride]. Therapie. 2002;57(5):473–483
  69. Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract. 2006;60(10):1157–1165
  70. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–1557discussion 64
  71. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients’ treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996;16(3):262–282
  72. Estabrooks C, Goel V, Thiel E, Pinfold P, Sawka C, Williams I. Decision aids: are they worth it? A systematic review. J Health Serv Res Policy. 2001;6(3):170–182
  73. O’Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009(3):CD001431.
  74. Dowding D, Swanson V, Bland R, Thomson P, Mair C, Morrison A, et al. The development and preliminary evaluation of a decision aid based on decision analysis for two treatment conditions: benign prostatic hyperplasia and hypertension. Patient Educ Couns. 2004;52(2):209–215
  75. Wills CE, Holmes-Rovner M, Rovner D, Lillie J, Kelly-Blake K, Bonham V, et al. Treatment preference patterns during a videotape decision aid for benign prostatic hyperplasia (BPH). Patient Educ Couns. 2006;61(1):16–22
  76. Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2004;172(6 Pt 1):2321–2325
  77. Feldman-Stewart D, Brennenstuhl S, Brundage MD. The information needed by Canadian early-stage prostate cancer patients for decision-making: stable over a decade. Patient Educ Couns. 2008;73(3):437–442
  78. Bungay H, Cappello R. ‘As long as the doctors know what they are doing’: trust or ambivalence about patient information among elderly men with prostate cancer?. Eur J Cancer Care (Engl). 2009;18(5):470–476
  79. Davison BJ, Oliffe JL, Pickles T, Mroz L. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum. 2009;36(1):89–96
  80. Fischer M, Visser A, Voerman B, Garssen B, van Andel G, Bensing J. Treatment decision making in prostate cancer: patients’ participation in complex decisions. Patient Educ Couns. 2006;63(3):308–313
  81. McKinstry B. Do patients wish to be involved in decision making in the consultation? A cross sectional survey with video vignettes. BMJ. 2000;321(7265):867–871
  82. Roehrborn CG. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004;93(Suppl 1):21–26

PII: S1875-6867(10)00026-6

doi: 10.1016/j.jomh.2009.12.007

journal of men's health
Volume 7, Issue 2 , Pages 113-124 , June 2010

Article Tools

* Image Usage & Resolution